

North America Radiopharmaceutical Theranostics Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Product Type [Alpha Emitters, Beta Emitters, and Positron Emission Tomography (PET) Tracers], Radioisotope [Technetium-99, Gallium-68, Iodine-131, Iodine-123, Yttrium-90 (Y-90), Fluorine-18 (18F), Lutetium (Lu) 177, Copper (Cu) 67, Copper (Cu) 64, and Others], Source (Nuclear Reactors and Cyclotrons), Application [Targeted Therapeutic (Rx) and Companion Diagnostic (CDx)], Indication (Oncology, Cardiology, Neurology, and Others), and End User (Hospitals, Diagnostic Imaging Centers, Academic and Research Institutes, and Others)

<https://marketpublishers.com/r/N43B2B7B501DEN.html>

Date: March 2023

Pages: 185

Price: US\$ 3,000.00 (Single User License)

ID: N43B2B7B501DEN

Abstracts

The North America radiopharmaceutical theranostics market is expected to reach US\$ 1,529.88 million by 2028 from US\$ 795.88 million in 2022; it is estimated to grow at a CAGR of 11.5% from 2022 to 2028.

The increasing incidences of chronic diseases, presence of supportive government plans, growing strategic initiatives by market players, and development of innovative radiotherapies are among the key forces bolstering the market. However, regulatory challenges for the approval of radiopharmaceutical theranostics hinder the North

America radiopharmaceutical theranostics market growth.

Radiopharmaceuticals are important in the diagnosis and therapy of cancer; a diagnostic scan with ^{123}I , ^{124}I , or low-activity ^{131}I -iodide is followed by therapy with high-activity ^{131}I -iodide. Similarly, adrenergic tumors such as pheochromocytoma and neuroblastoma can be imaged with ^{123}I -meta-iodobenzylguanidine and treated with ^{131}I -metaiodobenzylguanidine. Bone scintigraphy can be used to select patients with painful bone metastases that progressed from prostate cancer. They might benefit from treatment with beta- or alpha-particle-emitting bone-seeking agents, the newest and most successful of which is ^{223}Ra radium chloride. Somatostatin receptor targeting peptides for diagnosing and treating neuroendocrine tumors with agents such as ^{68}Ga -DOTATATE and ^{177}Lu -DOTATATE, respectively, are among the recently established theranostics.

Atherosclerosis remains a dominant cause of cardiovascular diseases (CVDs). It acts as a life-threatening CVD resulting in chronic inflammation and abnormal lipid proliferation, and it is often difficult to treat on time due to the lack of noticeable symptoms in the initial phases. Due to their associated complexity and pathophysiology, CVDs have been presenting major challenges to healthcare systems in North American countries. Per the 2022 report by the Centers for Disease Control and Prevention (CDC), heart disease is a leading cause of death among men and women in the US. It was a cause of ~697,000 deaths, i.e., 1 in 5 deaths, in the US in 2020. A National Institute of Health (NIH) report states that theranostic nanoparticles have gained significant attention in the medical field, as the techniques help overcome complexities and pathophysiological complications associated with CVDs. Cardiovascular imaging of atherosclerosis patients provides pathophysiological evidence that can be used to treat these diseases. Further, theranostic nanoparticles can be combined with a range of imaging techniques, such as magnetic resonance imaging (MRI), positron emission tomography (PET), and computed tomography (CT). Various clinical research studies have been conducted in clinical laboratories so far. A three-in-one therapeutic complex has been constructed by combining a polymeric photoacoustic probe with nanoparticles-PLCDP@PMH. Clinical in-vivo evaluations reveal that the PLCDP@PMH supports the theranostics approach by enabling early-stage atherosclerosis detection in patients.

Radiopharmaceutical therapies (RPTs) involve injecting a particular radioactive drug (such as 200mCi for ^{177}Lu -PSMA and ^{177}Lu -DOTATATE) into patients undergoing therapy. However, upon injection, the doses delivered to organs and absorbed quantities of drugs show notable variations. Radiopharmaceutical therapies for tumors and normal tissues depend on absorbed doses; however, variations in absorption are

difficult to control. A fixed administered dosage results in the undertreatment of patients, possibly leading to cases of dose toxicity. Theranostic digital twins (TDTs) can be employed in the drug development process to overcome such limitations. The TDTs investigate optimal injected radioactive drugs among patients at the sites of injection, along with determining injection intervals and profiles, and suitable combinational radiopharmaceutical therapies. Additionally, TDTs coupled with appropriate computational tools can be used in predictive absorbed radiation dose modeling. Further, TDTs promise zero uncertainties in the clinical results generated, thus acting as a powerful tool for offering truly personalized treatments to patients. Thus, the use of TDTs in personalized radiopharmaceutical therapies provides lucrative opportunities for radiopharmaceutical theranostics market players.

Product Type Insights

Based on product type, the North America radiopharmaceutical theranostics market is segmented positron emission tomography (PET) tracers, beta emitters, and alpha emitters. In 2022, the positron emission tomography (PET) tracers segment held the largest market share in North America radiopharmaceutical theranostics market, and it is anticipated to register the highest CAGR during the forecast period (2022–2028). PET is an imaging technique that provides quantitative information on the distribution of PET radiopharmaceuticals in the body. PET imaging requires expensive equipment, which includes a cyclotron for radionuclide production, automated chemistry devices, purification instrumentation, and PET cameras. PET imaging is used in areas such as cardiology, neurology, and cancer diagnosis. PET may detect the early onset of disease before it is evident on other imaging tests. Better resolution can be achieved via PET using positron emitters, such as gallium-68 and fluorine-18. PET tracers featuring radioactive copper have also been developed as a promising alternative for existing hypoxia imaging techniques due to their high membrane permeability and low redox potential. The success of Ga-PSMA-11 further inspired the development of PSMA-targeting PET tracers for imaging prostate cancer. Additionally, theranostics PET tracers are progressively used in radiopharmaceutical drug development and its application. Theranostic PET tracers have the potential to serve as a noninvasive whole-body navigator, which helps select the most effective drug candidates, and determine optimal dosage and administration route. Thus, benefits such as higher resolution, and quantification of activity boost the North America radiopharmaceutical theranostics market for the PET tracers segment.

Radioisotope Insights

Based on radioisotope, the North America radiopharmaceutical theranostics market is segmented Lutetium (Lu) 177, Gallium-68, Iodine-131, Iodine-123, Technetium-99, Yttrium-90 (Y-90), Copper (Cu) 64, 18F, Copper (Cu) 67, and others. In 2022, the Lutetium (Lu) 177 segment held the largest market share in North America radiopharmaceutical theranostics market, and it is anticipated to register the highest CAGR of 12.7% during the forecast period (2022–2028). Lutetium-177 (177Lu) is the latest addition to the field of nuclear medicine. It has potential to become one of the most extensively used therapeutic radionuclides in the coming years. Lu-177 PSMA therapy for cancer theranostic is employed to treat advanced prostate cancer cases. Lu-177 octreotate therapy is used to treat neuroendocrine tumors (NETs), including head and neck cancers and gastrointestinal tumors. Lutetium therapy (lutetium-177-DOTA-oxodotreotide) has been identified as targeted radionuclide therapy or peptide receptor radionuclide therapy (PRRT). The US Food and Drug Administration (FDA) has approved 177Lu-labeled DOTA-TATE for peptide receptor radionuclide therapy (PRRT).

Source Insights

Based on source, the North America radiopharmaceutical theranostics market is divided into cyclotrons and nuclear reactors. In 2022, the cyclotrons segment held a larger market share in North America radiopharmaceutical theranostics market and is anticipated to register a higher CAGR during the forecast period (2022–2028). Cyclotrons are best suited for producing proton-rich radioisotopes such as Fluorine-18 (18F). Commercially available cyclotron-produced medical radioisotope involves Carbon-11, Nitrogen-13, Oxygen-15, Fluorine-18 (18F), Copper-64, Gallium-67, Iodine-123, and Thallium-201. According to the International Atomic Energy Agency (IAEA) 2023 report, the most frequent radioisotope produced through cyclotrons are those with short half-lives, particularly fluorine-18, carbon-11, oxygen-15, and nitrogen-13, intended for imaging techniques such as positron emission tomography (PET). Cyclotrons account for almost 95% of the production of radiopharmaceuticals used in PET. Additionally, the demand for cyclotrons is increasing as radionuclides are majorly used in research, diagnosis, and treatment of a range of life-threatening diseases such as cancer, Parkinson's, Alzheimer's, and insomnia. Further, medical imaging techniques such as PET and SPECT depend on cyclotron-produced radioisotopes.

Application Insights

Based on application, the North America radiopharmaceutical theranostics market is

bifurcated into targeted therapeutic (Rx) and companion diagnostic (CDx). The targeted therapeutic (Rx) segment held a larger market share in North America radiopharmaceutical theranostics market in 2022, and it is expected to register a higher CAGR during the forecast period. Targeted therapeutics have emerged as a promising strategy for treating harmful clinical conditions, such as cancer. For example, 'radionuclide,' a type of radiation therapy, uses a cell-targeting molecule such as a monoclonal antibody injected into the body. Further, the cell-targeting molecule binds to a specific target molecule on cancer cells, subsequently killing the targeted cancer cells; the mechanism ensures minimum harm to normal cells. Targeted therapeutics are used for treating prostate cancer and other types of cancers. This is well understood by the following case of targeting somatostatin receptors in neuroendocrine pancreatic tumors.

⁶⁸Ga has been developed for somatostatin receptor imaging such as DOTATOC, DOTATATE, and DOTANOC. A somatostatin-receptor targeted therapy can be utilized for neoadjuvant therapy that renders inoperable pNET resectable by utilizing ¹⁷⁷Lu-DOTATATE (27) and ⁹⁰Y-DOTATATE (28). ⁹⁰Y is a beta-emitting radionuclide best suited for bulky pancreatic tumors. Additionally, ¹⁷⁷Lu-DOTATOC and ²¹³Bi-DOTATOC have revealed relatively high biological effectiveness, and they are effectively responsible for decreasing the survival of pancreatic adenocarcinoma cells.

Indication Insights

Based on indication, the North America radiopharmaceutical theranostics market is segmented oncology, neurology, cardiology, and others. The oncology segment held the largest market share in 2022, and it is anticipated to register the highest CAGR during the forecast period (2022–2028). Theranostics methods involve administering nanoparticles into the patient's body and using photodynamic therapy, which paves the way for personalized medicine. These methods can be applied in the treatment of esophageal cancer, prostate cancer, and breast cancer, in the treatment of actinic keratosis, actinic cheilitis, Bowen's disease, basal cell epithelioma, and macular degeneration. Therapeutic radiopharmaceuticals for cancer treatment are predominantly labeled with beta-emitting radionuclides. The radionuclides I-131, Lu-177, and Yttrium-90 (Y-90) are frequently used for this purpose. Upon decay, the emitted beta-particles travel 1–12 mm through tissue while losing energy and causing cytotoxic damage to the cell to induce apoptosis. Alternatively, and more recently, alpha-emitting radionuclides, e.g., At-211 or Ac-225, have been explored for therapeutic applications. Theranostics has been successfully used by clinicians and patients in treating prostate cancer. Thus, the strong clinical need for these therapies and targeted treatments in

oncology continue to fuel the market for the oncology segment during the forecast period.

End User Insights

Based on end user, the North America radiopharmaceutical theranostics market is segmented hospitals, diagnostic imaging centers, academic and research institutes, and others. The hospitals segment held the largest market share in 2022. However, academic and research institutes segment is anticipated to register the highest CAGR during the forecast period (2022–2028). Hospitals employ technologically advanced systems to treat cardiac aneurysms, neurology aneurysms, oncology tumors, and other similar conditions. The rising prevalence of various diseases and an increasing number of hospitals contribute to the growth of the market for hospitals segment.

Contents

1. INTRODUCTION

- 1.1 Scope of the Study
- 1.2 The Insight Partners Research Report Guidance
- 1.3 Market Segmentation
 - 1.3.1 North America Radiopharmaceutical Theranostics Market – by Product Type
 - 1.3.2 North America Radiopharmaceutical Theranostics Market – by Radioisotope
 - 1.3.3 North America Radiopharmaceutical Theranostics Market – by Source
 - 1.3.4 North America Radiopharmaceutical Theranostics Market – by Application
 - 1.3.5 North America Radiopharmaceutical Theranostics Market – by Indication
 - 1.3.6 North America Radiopharmaceutical Theranostics Market – by End User
 - 1.3.7 North America Radiopharmaceutical Theranostics Market – by Country

2. NORTH AMERICA RADIOPHARMACEUTICAL THERANOSTICS MARKET – KEY TAKEAWAYS

3. RESEARCH METHODOLOGY

- 3.1 Coverage
- 3.2 Secondary Research
- 3.3 Primary Research

4. NORTH AMERICA RADIOPHARMACEUTICAL THERANOSTICS MARKET – MARKET LANDSCAPE

- 4.1 Overview
- 4.2 PEST Analysis
 - 4.2.1 North America – PEST Analysis
- 4.3 Experts' Opinion

5. RADIOPHARMACEUTICAL THERANOSTICS MARKET – KEY MARKET DYNAMICS

- 5.1 Market Drivers
 - 5.1.1 Rising Incidence of Cancer
 - 5.1.2 Rising Application in Treatment of Cardiovascular Disorders

5.2 Market Restraints

5.2.1 Regulatory Challenges for Approval of Radiopharmaceutical Theranostics

5.3 Market Opportunities

5.3.1 Theranostic Digital Twins for Personalized Radiopharmaceutical Therapies

5.4 Future Trends

5.4.1 Radiopharmaceutical Theranostics in Nuclear Medicine

5.5 Impact Analysis

6. NORTH AMERICA RADIOPHARMACEUTICAL THERANOSTICS MARKET ANALYSIS

6.1 North America Radiopharmaceutical Theranostics Market Revenue Forecast and Analysis

6.1.1 Market Positioning of Key Players in Radiopharmaceutical Theranostics Market

6.1.1.1 GE HealthCare Technologies Inc

6.1.1.2 Curium

7. NORTH AMERICA RADIOPHARMACEUTICAL THERANOSTICS MARKET ANALYSIS – BY PRODUCT TYPE

7.1 Overview

7.1.1 Alpha Emitters

7.1.1.1 Overview

7.1.1.2 Alpha Emitters: North America Radiopharmaceutical Theranostics Market – Revenue and Forecast to 2028 (US\$ Million)

7.1.2 Beta Emitters

7.1.2.1 Overview

7.1.2.2 Beta Emitters: North America Radiopharmaceutical Theranostics Market – Revenue and Forecast to 2028 (US\$ Million)

7.1.3 Positron Emission Tomography (PET) Tracers

7.1.3.1 Overview

7.1.3.2 Positron Emission Tomography (PET) Tracers: North America Radiopharmaceutical Theranostics Market – Revenue and Forecast to 2028 (US\$ Million)

8. NORTH AMERICA RADIOPHARMACEUTICAL THERANOSTICS MARKET ANALYSIS – BY RADIOISOTOPE

8.1 Overview

8.1.1 Technetium-99

8.1.1.1 Overview

8.1.1.2 Technetium-99: North America Radiopharmaceutical Theranostics Market – Revenue and Forecast to 2028 (US\$ Million)

8.1.2 Gallium-68

8.1.2.1 Overview

8.1.2.2 Gallium-68: North America Radiopharmaceutical Theranostics Market – Revenue and Forecast to 2028 (US\$ Million)

8.1.3 Iodine-131

8.1.3.1 Overview

8.1.3.2 Iodine-131: North America Radiopharmaceutical Theranostics Market – Revenue and Forecast to 2028 (US\$ Million)

8.1.4 Iodine-123

8.1.4.1 Overview

8.1.4.2 Iodine-123: North America Radiopharmaceutical Theranostics Market – Revenue and Forecast to 2028 (US\$ Million)

8.1.5 Fluorine-18 (18F)

8.1.5.1 Overview

8.1.5.2 Fluorine-18 (18F): North America Radiopharmaceutical Theranostics Market – Revenue and Forecast to 2028 (US\$ Million)

8.1.6 Yttrium-90 (Y-90)

8.1.6.1 Overview

8.1.6.2 Yttrium-90 (Y-90): North America Radiopharmaceutical Theranostics Market – Revenue and Forecast to 2028 (US\$ Million)

8.1.7 Lutetium (Lu)

8.1.7.1 Overview

8.1.7.2 Lutetium (Lu) 177: North America Radiopharmaceutical Theranostics Market – Revenue and Forecast to 2028 (US\$ Million)

8.1.8 Copper (Cu)

8.1.8.1 Overview

8.1.8.2 Copper (Cu) 67: North America Radiopharmaceutical Theranostics Market – Revenue and Forecast to 2028 (US\$ Million)

8.1.9 Copper (Cu)

8.1.9.1 Overview

8.1.9.2 Copper (Cu) 64: North America Radiopharmaceutical Theranostics Market – Revenue and Forecast to 2028 (US\$ Million)

8.1.10 Others

8.1.10.1 Overview

8.1.10.2 Others: North America Radiopharmaceutical Theranostics Market – Revenue

and Forecast to 2028 (US\$ Million)

9. NORTH AMERICA RADIOPHARMACEUTICAL THERANOSTICS MARKET ANALYSIS – BY SOURCE

9.1 Overview

9.1.1 Nuclear Reactors

9.1.1.1 Overview

9.1.1.2 Nuclear Reactors: North America Radiopharmaceutical Theranostics Market Revenue and Forecasts to 2028 (US\$ Million)

9.1.2 Cyclotrons

9.1.2.1 Overview

9.1.2.2 Cyclotrons: North America Radiopharmaceutical Theranostics Market Revenue and Forecasts to 2028 (US\$ Million)

10. NORTH AMERICA RADIOPHARMACEUTICAL THERANOSTICS MARKET ANALYSIS – BY APPLICATION

10.1 Overview

10.1.1 Targeted Therapeutic (Rx)

10.1.1.1 Overview

10.1.1.2 Targeted Therapeutics (Rx): North America Radiopharmaceutical Theranostics Market Revenue and Forecasts to 2028 (US\$ Million)

10.1.2 Companion Diagnostic (CDx)

10.1.2.1 Overview

10.1.2.2 Companion Diagnostics (CDx): North America Radiopharmaceutical Theranostics Market Revenue and Forecasts to 2028 (US\$ Million)

11. NORTH AMERICA RADIOPHARMACEUTICAL THERANOSTICS MARKET ANALYSIS – BY INDICATION

11.1 Overview

11.1.1 Oncology

11.1.1.1 Overview

11.1.1.2 Oncology: North America Radiopharmaceutical Theranostics Market – Revenue and Forecast to 2028 (US\$ Million)

11.1.2 Neurology

11.1.2.1 Overview

11.1.2.2 Neurology: North America Radiopharmaceutical Theranostics Market Revenue

and Forecasts to 2028 (US\$ Million)

11.1.3 Cardiology

11.1.3.1 Overview

11.1.3.2 Cardiology: North America Radiopharmaceutical Theranostics Market – Revenue and Forecast to 2028 (US\$ Million)

11.1.4 Others

11.1.4.1 Overview

11.1.4.2 Others: North America Radiopharmaceutical Theranostics Market Revenue and Forecasts to 2028 (US\$ Million)

12. NORTH AMERICA RADIOPHARMACEUTICAL THERANOSTICS MARKET ANALYSIS – BY END USER

12.1 Overview

12.1.1 Hospitals

12.1.1.1 Overview

12.1.1.2 Hospitals: North America Radiopharmaceutical Theranostics Market Revenue and Forecasts to 2028 (US\$ Million)

12.1.2 Diagnostic Imaging Centers

12.1.2.1 Overview

12.1.2.2 Diagnostic Imaging Centers: North America Radiopharmaceutical Theranostics Market Revenue and Forecasts to 2028 (US\$ Million)

12.1.3 Academic & Research Institutes

12.1.3.1 Overview

12.1.3.2 Academic & Research Institutes: North America Radiopharmaceutical Theranostics Market Revenue and Forecasts to 2028 (US\$ Million)

12.1.4 Others

12.1.4.1 Overview

12.1.4.2 Others: North America Radiopharmaceutical Theranostics Market Revenue and Forecasts to 2028 (US\$ Million)

13. NORTH AMERICA RADIOPHARMACEUTICAL THERANOSTICS MARKET

13.1 Overview

13.1.1 North America Radiopharmaceutical Theranostics Market – Revenue and Forecast to 2028 (US\$ Million)

13.1.2 North America: Radiopharmaceutical Theranostics Market, by Product Type, 2019–2028 (US\$ Million)

13.1.3 North America: Radiopharmaceutical Theranostics Market, by Radioisotope,

2019–2028 (US\$ Million)

13.1.4 North America: Radiopharmaceutical Theranostics Market, by Source, 2019–2028 (US\$ Million)0

13.1.5 North America: Radiopharmaceutical Theranostics Market, by Application, 2019–2028 (US\$ Million)0

13.1.6 North America: Radiopharmaceutical Theranostics Market, by Indication, 2019–2028 (US\$ Million)1

13.1.7 North America: Radiopharmaceutical Theranostics Market, by End User, 2019–2028 (US\$ Million)1

13.1.7.1 United States: Radiopharmaceutical Theranostics Market – Revenue and Forecast to 2028 (US\$ Million)3

13.1.7.1.1 Overview3

13.1.7.1.2 United States Radiopharmaceutical Theranostics Market – Revenue and Forecast to 2028 (US\$ Million)4

13.1.7.1.3 United States Radiopharmaceutical Theranostics Market, by Product Type, 2019–2028 (US\$ Million)5

13.1.7.1.4 United States Radiopharmaceutical Theranostics Market, by Radioisotope, 2019–2028 (US\$ Million)6

13.1.7.1.5 United States Radiopharmaceutical Theranostics Market, by Source, 2019–2028 (US\$ Million)7

13.1.7.1.6 United States Radiopharmaceutical Theranostics Market, by Application, 2019–2028 (US\$ Million)7

13.1.7.1.7 United States Radiopharmaceutical Theranostics Market, by Indication, 2019–2028 (US\$ Million)8

13.1.7.1.8 United States Radiopharmaceutical Theranostics Market, by End User, 2019–2028 (US\$ Million)8

13.1.7.2 Canada: Radiopharmaceutical Theranostics Market – Revenue and Forecast to 2028 (US\$ Million)9

13.1.7.2.1 Overview9

13.1.7.2.2 Canada Radiopharmaceutical Theranostics Market – Revenue and Forecast to 2028 (US\$ Million)0

13.1.7.2.3 Canada Radiopharmaceutical Theranostics Market, by Product type, 2019–2028 (US\$ Million)1

13.1.7.2.4 Canada Radiopharmaceutical Theranostics Market, by Radioisotope, 2019–2028 (US\$ Million)2

13.1.7.2.5 Canada Radiopharmaceutical Theranostics Market, by Source, 2019–2028 (US\$ Million)3

13.1.7.2.6 Canada Radiopharmaceutical Theranostics Market, by Application, 2019–2028 (US\$ Million)3

- 13.1.7.2.7 Canada Radiopharmaceutical Theranostics Market, by Indication, 2019–2028 (US\$ Million)4
- 13.1.7.2.8 Canada Radiopharmaceutical Theranostics Market, by End User, 2019–2028 (US\$ Million)4
- 13.1.7.3 Mexico: Radiopharmaceutical Theranostics Market – Revenue and Forecast to 2028 (US\$ Million)5
 - 13.1.7.3.1 Overview5
 - 13.1.7.3.2 Mexico Radiopharmaceutical Theranostics Market – Revenue and Forecast to 2028 (US\$ Million)6
 - 13.1.7.3.3 Mexico Radiopharmaceutical Theranostics Market, by Product Type, 2019–2028 (US\$ Million)7
 - 13.1.7.3.4 Mexico Radiopharmaceutical Theranostics Market, by Radioisotope, 2019–2028 (US\$ Million)8
 - 13.1.7.3.5 Mexico Radiopharmaceutical Theranostics Market, by Source, 2019–2028 (US\$ Million)9
 - 13.1.7.3.6 Mexico Radiopharmaceutical Theranostics Market, by Application, 2019–2028 (US\$ Million)9
 - 13.1.7.3.7 Mexico Radiopharmaceutical Theranostics Market, by Indication, 2019–2028 (US\$ Million)0
 - 13.1.7.3.8 Mexico Radiopharmaceutical Theranostics Market, by End User, 2019–2028 (US\$ Million)1

14. NORTH AMERICA RADIOPHARMACEUTICAL THERANOSTICS MARKET: IMPACT ASSESSMENT OF COVID-19 PANDEMIC2

- 14.1 Impact Analysis of COVID-19 Pandemic on North America Radiopharmaceutical Theranostics Market2

15. NORTH AMERICA RADIOPHARMACEUTICAL THERANOSTICS MARKET – INDUSTRY LANDSCAPE5

- 15.1 Overview5
- 15.2 Growth Strategies in North America Radiopharmaceutical Theranostics Market (%)6
- 15.3 Organic Developments7
 - 15.3.1 Overview7
- 15.4 Inorganic Developments1
 - 15.4.1 Overview1

16. COMPANY PROFILES5

- 16.1 Bayer AG5
 - 16.1.1 Key Facts5
 - 16.1.2 Business Description5
 - 16.1.3 Products and Services6
 - 16.1.4 Financial Overview7
 - 16.1.5 SWOT Analysis0
 - 16.1.6 Key Developments1
- 16.2 GE HealthCare Technologies Inc2
 - 16.2.1 Key Facts2
 - 16.2.2 Business Description2
 - 16.2.3 Products and Services3
 - 16.2.4 Financial Overview4
 - 16.2.5 SWOT Analysis6
 - 16.2.6 Key Developments7
- 16.3 Curium9
 - 16.3.1 Key Facts9
 - 16.3.2 Business Description9
 - 16.3.3 Products and Services0
 - 16.3.4 Financial Overview0
 - 16.3.5 SWOT Analysis1
 - 16.3.6 Key Developments2
- 16.4 Lantheus Medical Imaging, Inc.3
 - 16.4.1 Key Facts3
 - 16.4.2 Business Description3
 - 16.4.3 Products and Services4
 - 16.4.4 Financial Overview4
 - 16.4.5 SWOT Analysis6
 - 16.4.6 Key Developments7
- 16.5 Telix Pharmaceuticals Ltd.8
 - 16.5.1 Key Facts8
 - 16.5.2 Business Description8
 - 16.5.3 Products and Services9
 - 16.5.4 Financial Overview9
 - 16.5.5 SWOT Analysis1
 - 16.5.6 Key Developments2
- 16.6 Cardinal Health Inc3
 - 16.6.1 Key Facts3

16.6.2 Business Description	3
16.6.3 Products and Services	4
16.6.4 Financial Overview	4
16.6.5 SWOT Analysis	6
16.6.6 Key Developments	7
16.7 Advanced Accelerator Applications S.A.	8
16.7.1 Key Facts	8
16.7.2 Business Description	8
16.7.3 Products and Services	9
16.7.4 Financial Overview	9
16.7.5 SWOT Analysis	0
16.7.6 Key Developments	1
16.8 Jubilant Radiopharma	2
16.8.1 Key Facts	2
16.8.2 Business Description	2
16.8.3 Products and Services	3
16.8.4 Financial Overview	3
16.8.5 SWOT Analysis	4
16.8.6 Key Developments	5
16.9 Theragnostics	6
16.9.1 Key Facts	6
16.9.2 Business Description	6
16.9.3 Products and Services	6
16.9.4 Financial Overview	6
16.9.5 SWOT Analysis	7
16.9.6 Key Developments	8
16.10 NuView Life Sciences	9
16.10.1 Key Facts	9
16.10.2 Business Description	9
16.10.3 Products and Services	9
16.10.4 Financial Overview	0
16.10.5 SWOT Analysis	0
16.10.6 Key Developments	1

17. APPENDIX2

17.1 About The Insight Partners	2
17.2 Glossary of Terms	3

List Of Tables

LIST OF TABLES

Table 1. North America Radiopharmaceutical Theranostics Market, by Product Type – Revenue and Forecast to 2028 (US\$ Million)

Table 2. North America Radiopharmaceutical Theranostics Market, by Radioisotope – Revenue and Forecast to 2028 (US\$ Million)

Table 3. North America Radiopharmaceutical Theranostics Market, by Source – Revenue and Forecast to 2028 (US\$ Million)

Table 4. North America Radiopharmaceutical Theranostics Market, by Application – Revenue and Forecast to 2028 (US\$ Million)

Table 5. North America Radiopharmaceutical Theranostics Market, by Indication – Revenue and Forecast to 2028 (US\$ Million)

Table 6. North America Radiopharmaceutical Theranostics Market, by End User – Revenue and Forecast to 2028 (US\$ Million)

Table 7. United States Radiopharmaceutical Theranostics Market, by Product Type – Revenue and Forecast to 2028 (US\$ Million)3

Table 8. United States Radiopharmaceutical Theranostics Market, by Radioisotope – Revenue and Forecast to 2028 (US\$ Million)4

Table 9. United States Radiopharmaceutical Theranostics Market, by Source – Revenue and Forecast to 2028 (US\$ Million)5

Table 10. United States Radiopharmaceutical Theranostics Market, by Application – Revenue and Forecast to 2028 (US\$ Million)5

Table 11. United States Radiopharmaceutical Theranostics Market, by Indication – Revenue and Forecast to 2028 (US\$ Million)6

Table 12. United States Radiopharmaceutical Theranostics Market, by End User – Revenue and Forecast to 2028 (US\$ Million)6

Table 13. Canada Radiopharmaceutical Theranostics Market, by Product type – Revenue and Forecast to 2028 (US\$ Million)9

Table 14. Canada Radiopharmaceutical Theranostics Market, by Radioisotope – Revenue and Forecast to 2028 (US\$ Million)0

Table 15. Canada Radiopharmaceutical Theranostics Market, by Source – Revenue and Forecast to 2028 (US\$ Million)1

Table 16. Canada Radiopharmaceutical Theranostics Market, by Application – Revenue and Forecast to 2028 (US\$ Million)1

Table 17. Canada Radiopharmaceutical Theranostics Market, by Indication – Revenue and Forecast to 2028 (US\$ Million)2

Table 18. Canada Radiopharmaceutical Theranostics Market, by End User – Revenue

and Forecast to 2028 (US\$ Million)2

Table 19. Mexico Radiopharmaceutical Theranostics Market, by Product Type – Revenue and Forecast to 2028 (US\$ Million)5

Table 20. Mexico Radiopharmaceutical Theranostics Market, by Radioisotope – Revenue and Forecast to 2028 (US\$ Million)6

Table 21. Mexico Radiopharmaceutical Theranostics Market, by Source – Revenue and Forecast to 2028 (US\$ Million)7

Table 22. Mexico Radiopharmaceutical Theranostics Market, by Application – Revenue and Forecast to 2028 (US\$ Million)7

Table 23. Mexico Radiopharmaceutical Theranostics Market, by Indication – Revenue and Forecast to 2028 (US\$ Million)8

Table 24. Mexico Radiopharmaceutical Theranostics Market, by End User – Revenue and Forecast to 2028 (US\$ Million)9

Table 25. Organic Developments in the North America Radiopharmaceutical Theranostics Market5

Table 26. Inorganic Developments in the North America Radiopharmaceutical Theranostics Market9

Table 27. Glossary of Terms0

List Of Figures

LIST OF FIGURES

- Figure 1. Radiopharmaceutical Theranostics Market Segmentation
- Figure 2. Radiopharmaceutical Theranostics Market Segmentation, by Region
- Figure 3. North America Radiopharmaceutical Theranostics Market Overview
- Figure 4. Positron Emission Tomography (PET) Tracers Held Largest Share of Product Type Segment in Radiopharmaceutical Theranostics Market
- Figure 5. U.S. to Show Significant Growth in Radiopharmaceutical Theranostics Market During Forecast Period
- Figure 6. North America Radiopharmaceutical Theranostics Market – Leading Country Markets (US\$ Million)
- Figure 7. North America Radiopharmaceutical Theranostics Market, Industry Landscape
- Figure 8. North America PEST Analysis
- Figure 9. Radiopharmaceutical Theranostics Market: Impact Analysis of Drivers and Restraints
- Figure 10. North America Radiopharmaceutical Theranostics Market – Revenue Forecast and Analysis – 2020–2028
- Figure 11. North America Radiopharmaceutical Theranostics Market, by Product Type, 2021 & 2028 (%)
- Figure 12. Alpha Emitters: North America Radiopharmaceutical Theranostics Market – Revenue and Forecast to 2028 (US\$ Million)
- Figure 13. Beta Emitters: North America Radiopharmaceutical Theranostics Market – Revenue and Forecast to 2028 (US\$ Million)
- Figure 14. Positron Emission Tomography (PET) Tracers: North America Radiopharmaceutical Theranostics Market – Revenue and Forecast to 2028 (US\$ Million)
- Figure 15. North America Radiopharmaceutical Theranostics Market, by Radioisotope, 2021 & 2028 (%)
- Figure 16. Technetium-99: North America Radiopharmaceutical Theranostics Market – Revenue and Forecast to 2028 (US\$ Million)
- Figure 17. Gallium-68: North America Radiopharmaceutical Theranostics Market – Revenue and Forecast to 2028 (US\$ Million)
- Figure 18. Iodine-131: North America Radiopharmaceutical Theranostics Market – Revenue and Forecast to 2028 (US\$ Million)
- Figure 19. Iodine-123: North America Radiopharmaceutical Theranostics Market – Revenue and Forecast to 2028 (US\$ Million)
- Figure 20. Fluorine-18 (18F): North America Radiopharmaceutical Theranostics Market

– Revenue and Forecast to 2028 (US\$ Million)

Figure 21. Yttrium-90 (Y-90): North America Radiopharmaceutical Theranostics Market

– Revenue and Forecast to 2028 (US\$ Million)

Figure 22. Lutetium (Lu) 177: North America Radiopharmaceutical Theranostics Market

– Revenue and Forecast to 2028 (US\$ Million)

Figure 23. Copper (Cu) 67: North America Radiopharmaceutical Theranostics Market – Revenue and Forecast to 2028 (US\$ Million)

Figure 24. Copper (Cu) 64: North America Radiopharmaceutical Theranostics Market – Revenue and Forecast to 2028 (US\$ Million)

Figure 25. Others: North America Radiopharmaceutical Theranostics Market – Revenue and Forecast to 2028 (US\$ Million)

Figure 26. North America Radiopharmaceutical Theranostics Market, by Source, 2021 & 2028 (%)

Figure 27. Nuclear Reactors Market Revenue and Forecasts to 2028 (US\$ Million)

Figure 28. Cyclotrons Market Revenue and Forecasts to 2028 (US\$ Million)

Figure 29. North America Radiopharmaceutical Theranostics Market, by Application, 2021 & 2028 (%)

Figure 30. Targeted Therapeutics (Rx) Market Revenue and Forecasts to 2028 (US\$ Million)

Figure 31. Companion Diagnostics (CDx) Market Revenue and Forecasts to 2028 (US\$ Million)

Figure 32. North America Radiopharmaceutical Theranostics Market, by Indication, 2021 & 2028 (%)

Figure 33. Oncology: North America Radiopharmaceutical Theranostics Market – Revenue and Forecast to 2028 (US\$ Million)

Figure 34. Neurology Market Revenue and Forecasts to 2028 (US\$ Million)

Figure 35. Cardiology: North America Radiopharmaceutical Theranostics Market – Revenue and Forecast to 2028 (US\$ Million)

Figure 36. Others Market Revenue and Forecasts to 2028 (US\$ Million)

Figure 37. North America Radiopharmaceutical Theranostics Market, by End User, 2021 & 2028 (%)

Figure 38. Hospitals Market Revenue and Forecasts to 2028 (US\$ Million)

Figure 39. Diagnostic Imaging Centers Market Revenue and Forecasts to 2028 (US\$ Million)

Figure 40. Academic & Research Institutes Market Revenue and Forecasts to 2028 (US\$ Million)

Figure 41. Others Market Revenue and Forecasts to 2028 (US\$ Million)

Figure 42. North America Radiopharmaceutical Theranostics Market, by Key Country – Revenue (2021) (US\$ Million)

Figure 43. North America Radiopharmaceutical Theranostics Market – Revenue and Forecast to 2028 (US\$ Million)

Figure 44. North America Radiopharmaceutical Theranostics Market, by Country, 2021 & 2028 (%)⁰

Figure 45. United States Radiopharmaceutical Theranostics Market – Revenue and Forecast to 2028 (US\$ Million)²

Figure 46. Canada Radiopharmaceutical Theranostics Market – Revenue and Forecast to 2028 (US\$ Million)⁸

Figure 47. Mexico Radiopharmaceutical Theranostics Market – Revenue and Forecast to 2028 (US\$ Million)⁴

Figure 48. Impact of COVID-19 Pandemic on North America Markets²

Figure 49. Growth Strategies in North America Radiopharmaceutical Theranostics Market (%)⁴

I would like to order

Product name: North America Radiopharmaceutical Theranostics Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Product Type [Alpha Emitters, Beta Emitters, and Positron Emission Tomography (PET) Tracers], Radioisotope [Technetium-99, Gallium-68, Iodine-131, Iodine-123, Yttrium-90 (Y-90), Fluorine-18 (18F), Lutetium (Lu) 177, Copper (Cu) 67, Copper (Cu) 64, and Others], Source (Nuclear Reactors and Cyclotrons), Application [Targeted Therapeutic (Rx) and Companion Diagnostic (CDx)], Indication (Oncology, Cardiology, Neurology, and Others), and End User (Hospitals, Diagnostic Imaging Centers, Academic and Research Institutes, and Others)

Product link: <https://marketpublishers.com/r/N43B2B7B501DEN.html>

Price: US\$ 3,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/N43B2B7B501DEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970